Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.
Purity:
>95%
CAS Number:
[357613-86-6]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted